Hodgkin Disease Clinical Trial
— pet-ctVerified date | November 2017 |
Source | Hospital Sao Rafael |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Identify the best combination of predictive variables that influence ionizing radiation dose and improved image quality through analysis and quantification of PET-CT images in simulators and patients.
Status | Completed |
Enrollment | 335 |
Est. completion date | March 2016 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Healthy volunteers; - Both genders; - Age over 18 years; - Clinical indication for PET-CT scan. Exclusion Criteria: - Pregnant women; - Patients who have lesions in the liver metabolically active whether primary or metastatic; - Patients with movement difficulties. |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital Sao Rafael | Salvador | Bahia |
Lead Sponsor | Collaborator |
---|---|
Hospital Sao Rafael |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Correlation of body weight with the variation coefficient (image noise). | The image noise will be measured by VOI (Volume Of Interest) in the images. The units of measure will be kilograms (kg) for body weight, and percentage for the variation coefficient. | 360 seconds | |
Secondary | Correlation of dose-regimen with the variation coefficient (image noise). | The dose-regimen will be calculated based on radiation dose and body surface. The image noise will be measured by VOI (Volume Of Interest) in the images. The units of measure will be MegaBecquerel per kilogram (MBq/kg) for dose-regimen, and percentage for the variation coefficient. | 360 seconds | |
Secondary | Correlation of acquisition protocol time with the variation coefficient (image noise). | Images will be acquired every 30 seconds until a maximum of 360 seconds. The image noise will be measured by VOI (Volume Of Interest) in the images. The units of measure will be seconds for the acquisition time, and percentage for the variation coefficient. | 360 seconds |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Active, not recruiting |
NCT02979522 -
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00540007 -
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT01676805 -
Tissue Collection for Studies of Lymph Cancer
|
||
Terminated |
NCT00916045 -
Pilot Study of Unrelated Cord Blood Transplantation
|
Phase 2 | |
Completed |
NCT00534989 -
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
|
N/A | |
Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
Completed |
NCT00062868 -
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
|
Phase 1 | |
Completed |
NCT00388349 -
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
|
Phase 2 | |
Recruiting |
NCT05255601 -
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT01716806 -
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
|
Phase 2 | |
Active, not recruiting |
NCT04998331 -
A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin
|
||
Completed |
NCT02389101 -
Molecular and Whole-body MR Imaging in Lymphomas
|
N/A | |
Completed |
NCT00871702 -
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
|
Phase 1 | |
Recruiting |
NCT02589548 -
Brazilian Prospective Hodgkin Lymphoma Registry
|
||
Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 | |
Terminated |
NCT00514722 -
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
|
N/A | |
Terminated |
NCT00225173 -
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
|
Phase 2 | |
Recruiting |
NCT06093334 -
Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD
|
N/A |